Currently Viewing:
Newsroom
Currently Reading
Polypharmacy Plays a Role in Patients With Relapsing-Remitting Multiple Sclerosis
February 17, 2019 – Laura Joszt
Review Find Moderate Evidence That Aerobic Exercise Lowers Number of Migraine Days
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019

First NGS-Based Companion Diagnostic Approved With Rucaparib for Advanced Ovarian Cancer

AJMC Staff
The FDA has provided accelerated approval for rupacarib along with the first next-generation sequencing—based companion diagnostic test, for the treatment of women with advanced ovarian cancer.
Women with advanced ovarian cancer that harbors a deleterious BRCA mutation and who have failed on at least 2 chemotherapy regimens can be treated with Clovis Oncology’s rucaparib (Rubraca), the FDA has announced.

Of the more than 22,000 women diagnosed with ovarian cancer each year, about 15% to 20% have a BRCA gene mutation. This results in faulty DNA repair pathways, which can promote tumor development. Rucaparib inhibits the enzyme poly ADP-ribose polymerase (PARP) that is involved in DNA damage repair—PARP inhibition in the cancer cells can prevent tumor growth.

Clovis submitted results from 2 single-arm clinical trials in 106 patients with ovarian cancer who had failed on 2 or more chemotherapy treatments. BRCA mutation in the ovarian tumor was confirmed in 96% of patients. A pooled analysis of the data confirmed a complete response rate of 9% and a partial response rate of 45%; the median duration of response was 9.2 months. Disease progression was observed in 9 patients.

“Today’s approval is another example of the trend we are seeing in developing targeted agents to treat cancers caused by specific mutations in a patient’s genes," Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and acting director of the FDA’s Oncology Center of Excellence, said in a statement. "Women with these gene abnormalities who have tried at least two chemotherapy treatments for their ovarian cancer now have an additional treatment option.”

Along with this approval, the FDA has also approved the first next-generation sequencing–based companion diagnostic test for Rubraca, FoundationFocus CDxBRCA.

The most common side effects associated with rucaparib are nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. The drug is also associated with serious risks, such as myelodysplastic syndrome, acute myeloid leukemia, and fetal harm.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!